Real-World Study Shows Sustained HAE Attack Reduction With Berotralstat скачать в хорошем качестве

Real-World Study Shows Sustained HAE Attack Reduction With Berotralstat

New real-world data published in Allergy, Asthma & Clinical Immunology demonstrate significant and sustained reductions in hereditary angioedema (HAE) attack rates following initiation of berotralstat. In one of the largest US cohorts to date, patients with both HAE-C1INH and HAE with normal C1 inhibitor experienced meaningful decreases in monthly attack rates at 12 months, with durability maintained through 18 months. In this interview, Raffi Tachdjian, MD, MPH, from UCLA Health, discusses the clinical implications of these findings, including how oral prophylaxis may influence sequencing decisions, adherence, and long-term disease control across diverse patient profiles. Key highlights: 01:35: How clinicians should think about starting or continuing berotralstat for patients with low baseline attack rates 02:03: Practical factors (adherence, persistance, tolerability) to consider when translating these findings into routine care 05:18: Unanswered questions about berotralstat Learn more about this real world data here: https://www.hcplive.com/view/sustaine... #hereditaryangiodema #hae #allergy